The prostate cancer 4Kscore test is the one product named in the Labcorp deal whose value is tied to a separate payment. On 15 October 2026, Labcorp announced an agreement to acquire select assets of OPKO Health’s BioReference Health subsidiary for $722 million in cash, with up to $150 million more payable based on revenue from the 4Kscore Test. The test, which the release describes as an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision, sits alongside laboratory businesses and more than 80 patient service centres in the package.
This report concentrates on the test: what the release says about it, why a contingent payment is attached, and what remains unknown.
Prostate cancer 4Kscore test: key takeaways
- What it is: a proprietary blood test the release calls FDA-approved.
- What it is for: predicting the likelihood of aggressive prostate cancer before a biopsy decision.
- Money: up to $150 million of the deal depends on its revenue, on top of $722 million in cash for the whole package.
- Not disclosed: the revenue threshold, the measurement period, test volumes and performance data.
- Status: the deal has not closed and is subject to regulatory approvals.
What the release says about the prostate cancer 4Kscore test
Labcorp’s release gives a one-sentence description: the 4Kscore Test is a proprietary, FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. It gives no test volumes, revenue, price, sensitivity or specificity, and it does not describe how the result is calculated. We therefore describe what the test is meant to do, not how well it does it.
Why the prostate cancer 4Kscore test is in demand
Screening and diagnosis of prostate cancer often involve a blood test for prostate-specific antigen, and the PSA fact sheet explains what PSA levels can and cannot show. An elevated PSA can lead to a biopsy, and not every biopsy finds aggressive disease. That is the gap tests such as 4Kscore aim to fill by adding information before the decision to biopsy. The National Cancer Institute offers general background on prostate cancer. The release does not make any clinical claims beyond its single descriptive sentence.
How the earnout ties to the prostate cancer 4Kscore test
The structure matters. Labcorp pays $722 million in cash at closing, subject to adjustment based on closing business revenues, for the clinical, women’s health, urology and corrections businesses, the patient service centres and the test. A further payment of up to $150 million depends on revenue from the 4Kscore Test. By our arithmetic, that is about 17% of the maximum total of $872 million. In practice, it means a meaningful part of the price is tied to how well the test sells after the deal.
Earnouts like this are a way to share risk between buyer and seller when the future of an asset is uncertain. For Labcorp, a lower payment follows weaker sales. For OPKO, strong sales raise the payout. The release does not give the threshold or timing, so outsiders cannot yet estimate the likelihood of payment.
What is not known about the prostate cancer 4Kscore test earnout
Several basic questions are open. It is not stated whether the revenue is measured on a calendar basis or over a fixed number of years after closing, whether the payment is all-or-nothing or scales with sales, or whether it counts only Labcorp’s own sales of the test or also those of others. These details determine how much of the $150 million is realistic. Until the companies file the agreement or describe the terms, any estimate of the likely payout would be speculation, and we do not offer one.
Where a test like this fits in a laboratory business
A branded test differs from routine laboratory work in that it is proprietary, so revenue depends on adoption by doctors and coverage by payers rather than on volume alone. Routine testing is a high-volume business with many competitors, while a proprietary test can be a differentiator but also carries the risk that clinicians and insurers do not adopt it. The release does not tell us which of these dynamics applies to 4Kscore, and we have not seen sales data.
What Labcorp and OPKO said about the prostate cancer 4Kscore test
Bryan Vaughn, Labcorp’s executive vice president and president of Diagnostics, said the acquisition “strengthens our ability to deliver affordable, high-quality, specialized diagnostic services.” OPKO’s chairman and chief executive, Dr Phillip Frost, said the transaction “will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business.” Neither statement addresses the test’s future role.
Risks and caveats for the prostate cancer 4Kscore test
- The release describes the test in one sentence and gives no performance data.
- The earnout depends on sales that may not materialise, and its terms are unpublished.
- The deal is not closed. Regulatory approvals and customary conditions apply.
- Labcorp’s expected first-year revenue of about $250 million is for all the acquired businesses together, not for the test alone.
In our assessment, the test is the most distinctive part of the package, because it is a branded product with a specific clinical use and a payment attached to it. Whether it becomes a growth driver depends on adoption by doctors and payers, which the release does not address. For related reading on prostate cancer screening policy, see our report on targeted prostate cancer screening in the UK and more healthcare services coverage. Risk factors are in each company’s filings on the SEC’s EDGAR database.
What to watch next for the prostate cancer 4Kscore test
- Disclosure of the earnout terms and any revenue milestones.
- Regulatory clearance and the closing date.
- Any plans from Labcorp for wider availability of the test.
- Published performance data and guideline positions.
Frequently asked questions
What is the prostate cancer 4Kscore test?
A proprietary, FDA-approved blood test that, per Labcorp, helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision.
How is the prostate cancer 4Kscore test connected to the price?
Up to $150 million of additional payment depends on its revenue.
Does Labcorp already offer it?
The release describes it as part of the assets being acquired. It does not say whether Labcorp offers a similar test.
When will the deal close?
No date was given. It is subject to regulatory approvals and customary conditions.
How we reported this: we relied on Labcorp’s announcement of 15 October 2026 and the NCI for background. The percentage is our own arithmetic. Last updated: 16 October 2026. This article is news reporting and not medical or investment advice.
